Cargando…

Validation of 2-year (123)I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure

AIMS: The aim of this study was to validate a four-parameter risk model including (123)I-meta-iodobenzylguanidine (MIBG) imaging, which was previously developed for predicting cardiac mortality, in a new cohort of patients with chronic heart failure (CHF). METHODS AND RESULTS: Clinical and outcome d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakajima, Kenichi, Nakata, Tomoaki, Doi, Takahiro, Kadokami, Toshiaki, Matsuo, Shinro, Konno, Tetsuo, Yamada, Takahisa, Jacobson, Arnold F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012774/ https://www.ncbi.nlm.nih.gov/pubmed/29415138 http://dx.doi.org/10.1093/ehjci/jey016

Ejemplares similares

Creation of mortality risk charts using (123)I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models
por: Nakajima, Kenichi, et al.
Publicado: (2016)

A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (123)I-metaiodobenzylguanidine imaging
por: Nakajima, Kenichi, et al.
Publicado: (2014)

(123)I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases
por: Nakajima, Kenichi, et al.
Publicado: (2016)

Machine learning-based risk model using (123)I-metaiodobenzylguanidine to differentially predict modes of cardiac death in heart failure
por: Nakajima, Kenichi, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA
por: O’Day, Ken, et al.
Publicado: (2016)

Standardization of (123)I-meta-iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications
por: Nakajima, Kenichi, et al.
Publicado: (2017)

Cross calibration of (123)I-meta-iodobenzylguanidine heart-to-mediastinum ratio with D-SPECT planogram and Anger camera
por: Nakajima, Kenichi, et al.
Publicado: (2017)

Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure
por: Veltman, Caroline E., et al.
Publicado: (2012)

Impact of Diabetes on Cardiac Sympathetic Innervation in Patients With Heart Failure: A (123)I meta-iodobenzylguanidine ((123)I MIBG) scintigraphic study
por: Paolillo, Stefania, et al.
Publicado: (2013)

Diagnostic Accuracy of (123)I-Meta-Iodobenzylguanidine Myocardial Scintigraphy in Dementia with Lewy Bodies: A Multicenter Study
por: Yoshita, Mitsuhiro, et al.
Publicado: (2015)

Is (123)I-metaiodobenzylguanidine heart-to-mediastinum ratio dependent on age? From Japanese Society of Nuclear Medicine normal database
por: Nakajima, Kenichi, et al.
Publicado: (2018)

Iodine-123-meta-iodobenzylguanidine Myocardial Scintigraphy in Isolated Autonomic Failure: Potential Red Flag for Future Multiple System Atrophy
por: Baschieri, Francesca, et al.
Publicado: (2017)

Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations
por: Nakajima, Kenichi, et al.
Publicado: (2014)

Prediction of Long-term Cardiac Events by 123I-meta-Iodobenzylguanidine Imaging after acute Myocardial Infarction and Reperfusion Therapy
por: Nakamura, Manabu, et al.
Publicado: (2019)

(123)I-Meta-Iodobenzylguanidine Single-Photon Emission Computerized Tomography/Computerized Tomography Scintigraphy in the Management of Neuroblastoma
por: Biassoni, Lorenzo, et al.
Publicado: (2021)

Prognostic value of nutritional parameters in systolic heart failure with renal dysfunction
por: Doi, Takahiro, et al.
Publicado: (2022)

Cardiac (123)I-mIBG Imaging in Heart Failure
por: Verschure, Derk O., et al.
Publicado: (2022)

Evaluation of Cardiac Mitochondrial Function by a Nuclear Imaging Technique using Technetium-99m-MIBI Uptake Kinetics
por: Matsuo, Shinro, et al.
Publicado: (2013)

Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure
por: Doi, Takahiro, et al.
Publicado: (2023)

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)
por: Kuin, A, et al.
Publicado: (1999)

Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.
por: Armour, A., et al.
Publicado: (1994)

A convenient Simple Method for Synthesis of Meta-iodobenzylguanidine (MIBG)
por: Sheikholislam, Zahra, et al.
Publicado: (2013)

Impaired Cardiac Sympathetic Innervation Increases the Risk of Cardiac Events in Heart Failure Patients with Left Ventricular Hypertrophy and Mechanical Dyssynchrony
por: Doi, Takahiro, et al.
Publicado: (2021)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
por: Gaze, M. N., et al.
Publicado: (1992)

Synergistic prognostication of left ventricular hypertrophy and three‐dimensional mechanical dyssynchrony in heart failure
por: Doi, Takahiro, et al.
Publicado: (2020)

A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019)

A model of modified meta-iodobenzylguanidine conjugated gold nanoparticles for neuroblastoma treatment
por: Saimuang, Kween, et al.
Publicado: (2021)

Differentiation between mild and severe myocarditis using multiparametric cardiac magnetic resonance
por: Arai, Hideo, et al.
Publicado: (2023)

Identification of Myocardial Damage in Systemic Sclerosis: A Nuclear Cardiology Approach
por: Nakajima, Kenichi, et al.
Publicado: (2010)

Assessing myocardial circumferential strain using cardiovascular magnetic resonance after magnetic resonance-conditional cardiac resynchronization therapy
por: Arai, Hideo, et al.
Publicado: (2020)

Radiosynthesis of no-carrier-added meta-[(124)I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma
por: Green, Michael, et al.
Publicado: (2016)

Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma
por: Jimenez, Camilo, et al.
Publicado: (2022)

Author Correction: A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2022)

Machine learning-based prediction of conversion coefficients for I-123 metaiodobenzylguanidine heart-to-mediastinum ratio
por: Okuda, Koichi, et al.
Publicado: (2023)

Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ((123)I-MIBG) washout on calculated (123)I-MIBG myocardial washout
por: Verberne, Hein J., et al.
Publicado: (2009)

Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database
por: Nakajima, Kenichi, et al.
Publicado: (2016)

Diagnostic accuracy of an artificial neural network compared with statistical quantitation of myocardial perfusion images: a Japanese multicenter study
por: Nakajima, Kenichi, et al.
Publicado: (2017)

Comparison of phase dyssynchrony analysis using gated myocardial perfusion imaging with four software programs: Based on the Japanese Society of Nuclear Medicine working group normal database
por: Nakajima, Kenichi, et al.
Publicado: (2016)

Three-Dimensional Heart Segmentation and Absolute Quantitation of Cardiac (123)I-metaiodobenzylguanidine Sympathetic Imaging Using SPECT/CT
por: Saito, Shintaro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p0g6ksbrcfjmmpi94gq7dgbeqf